A PHASE IIIB, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS EMICIZUMAB IN PATIENTS FROM BIRTH TO 12 MONTHS OF AGE WITH HEMOPHILIA A WITHOUT INHIBITORS

Registry ID

MO41787

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

HOFFMANN-LA ROCHE LIMITED

Start date

2022-01-21

Last update

2020-11-19

Conditions

• HEMOPHILIA

Related clinical trials

• AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF MARSTACIMAB PROPHYLAXIS IN SEVERE (COAGULATION FACTOR ACTIVITY <1%) HEMOPHILIA A PARTICIPANTS WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY <=2%) WITH OR WITHOUT INHIBITORS
• ATLAS-OLE: AN OPEN-LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF FITUSIRAN IN PATIENTS WITH HEMOPHILIA A OR B, WITH OR WITHOUT INHIBITORY ANTIBODIES TO FACTOR VIII OR IX
• A MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB IN PATIENTS WITH MILD OR MODERATE HEMOPHILIA A WITHOUT FVIII INHIBITORS.
• ATLAS-PEDS: AN OPEN-LABEL, MULTINATIONAL STUDY OF FITUSIRAN PROPHYLAXIS IN MALE PEDIATRIC SUBJECTS AGED 1 TO LESS THAN 12 YEARS WITH HEMOPHILIA A OR B.

View on source registry